Carcinoma In Situ Clinical Trials in New York, New York
7 recruitingNew York, New York
Showing 1–7 of 7 trials
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled75 locationsNCT06545955
Recruiting
Phase 2
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011)
Urinary Bladder NeoplasmsCarcinoma In SituNon-Muscle Invasive Bladder Neoplasms
Merck Sharp & Dohme LLC308 enrolled89 locationsNCT06833073
Recruiting
Phase 2
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Ductal Carcinoma in Situ
QuantumLeap Healthcare Collaborative400 enrolled28 locationsNCT06075953
Recruiting
Project: Every Child for Younger Patients With Cancer
Malignant Solid NeoplasmNeuroendocrine NeoplasmCentral Nervous System Neoplasm+15 more
Children's Oncology Group75,000 enrolled278 locationsNCT02402244
Recruiting
Phase 1Phase 2
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
Non-muscle Invasive Bladder Cancer With Carcinoma in SituSuperficial Bladder Cancer
enGene, Inc.350 enrolled101 locationsNCT04752722
Recruiting
The PREDICT Registry:
DCISDuctal Breast Carcinoma In SituStage 0 Breast Cancer
PreludeDx3,000 enrolled30 locationsNCT03448926
Recruiting
Not Applicable
Women Informed to Screen Depending on Measures of Risk (Wisdom Study)
Breast CancerBreast Cancer ScreeningBreast Carcinoma in Situ
University of California, San Francisco100,000 enrolled11 locationsNCT02620852